Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Medullary Thyroid Cancer

Rare Cancers

Medullary Thyroid Cancer (MTC) Clinical Trials

Also called MTC, medullary thyroid carcinoma, sporadic MTC, thyroid C-cell cancer, parafollicular cell carcinoma

Medullary thyroid cancer (MTC) arises from the parafollicular C cells of the thyroid gland, which produce calcitonin. Unlike the more common papillary and follicular thyroid cancers that arise from thyroid follicular cells, MTC has distinct biology, treatment, and prognosis. Serum calcitonin and carcinoembryonic antigen (CEA) serve as tumor markers for diagnosis and monitoring.

In plain words, medullary thyroid cancer is a rare cancer that starts in a special type of cell in the thyroid gland called C cells. These cells make a hormone called calcitonin, and some cases are passed down in families through a gene change.

Get an email when new Medullary Thyroid Cancer trials open or the FDA decides. Get alerts

Medullary Thyroid Cancer

Where treatments stand, from ClinicalTrials.gov and FDA labels

Also 12 studies with no phase, like observational studies, and 1 phase 4 study following medicines after approval.

FDA review0

No decision pending. FDA calendar

FDA-approved medicines3

Caprelsa · Cometriq · Retevmo

Medullary Thyroid Cancer has 3 FDA-approved medicines, 19 open or active clinical trials (11 recruiting), and no pending FDA decision.

Labels checked October 21, 2026. Corticosteroids and immune globulins count once each.Download the data

Latest for Medullary Thyroid Cancer

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

More about Medullary Thyroid Cancer

About 75% of MTC cases are sporadic (no family history), while 25% are hereditary, caused by activating mutations in the RET proto-oncogene and associated with Multiple Endocrine Neoplasia type 2 (MEN 2A and MEN 2B) or Familial MTC (FMTC). Surgery (total thyroidectomy with lymph node dissection) is the primary treatment for localized disease.

Keep reading about Medullary Thyroid Cancer

For advanced or metastatic MTC, the treatment landscape changed dramatically with the FDA approval of selective RET inhibitors. Selpercatinib (Retevmo, Eli Lilly) received full FDA approval in September 2024 after the phase 3 LIBRETTO-531 trial showed superior progression-free survival compared to older multikinase inhibitors.

The older multikinase inhibitors vandetanib (Caprelsa, approved 2011) and cabozantinib (Cometriq, Exelixis, approved 2012) remain available but carry broader side-effect profiles. Pralsetinib (Gavreto) was previously approved for RET-altered MTC under accelerated approval, but that indication was voluntarily withdrawn in 2023 when the confirmatory trial proved infeasible.

RET mutation testing (germline for hereditary cases, somatic via NGS panels for sporadic advanced disease) is essential to guide treatment selection.

What are the symptoms of Medullary Thyroid Cancer?

These are common symptoms of Medullary Thyroid Cancer, and how strong they are varies from person to person.

  • A lump or nodule in the neck, often painless
  • Hoarseness or voice changes if the tumor presses on the recurrent laryngeal nerve
  • Difficulty swallowing (dysphagia)
  • Diarrhea, sometimes severe, from calcitonin excess
  • Flushing in advanced disease
  • Bone pain, cough, or shortness of breath if the cancer has spread

Who gets Medullary Thyroid Cancer?

Sporadic MTC typically presents between ages 40-60 and affects males and females equally. Hereditary MTC (25% of cases) is caused by germline RET proto-oncogene mutations and can present much earlier, sometimes in childhood. All populations are affected with no known ethnic or racial predisposition.

Risk factors for sporadic MTC are not well defined. Family history of MTC or MEN 2 syndromes is the strongest risk factor for hereditary disease.

Next steps: find trials you might fitsee approved treatmentsget help payingget alerts

Which medicines are FDA-approved for Medullary Thyroid Cancer?

There are currently 3 FDA-approved medications for Medullary Thyroid Cancer.

vandetanib
Genzyme Corporation
Search
cabozantinib
Exelixis, Inc.
Search

Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.

How to get help paying for Medullary Thyroid Cancer treatment

Charity funds and drugmaker programs for Medullary Thyroid Cancer, checked at the source.

Which insurance do you have? Pick one to see what fits. Tap it again to clear.
Your insurance
Charity funds
  • From a charity · The Assistance Fund
    Thyroid Cancer fund
    Waitlist

    Pays for: Copays, coinsurance, deductibles and other health-related expenses.

Status as each foundation showed it on November 16, 2026.

Every program and fund for Medullary Thyroid Cancer, by insurance →

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for Medullary Thyroid Cancer

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

The RET gene page lists every condition Orphanet links to the gene and the open trials that name it.

Finding labs...

Trusted Medullary Thyroid Cancer resources

Reputable organizations and medical references for learning more about Medullary Thyroid Cancer, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Medullary Thyroid Cancer

Use this Medullary Thyroid Cancer clinical trial finder to see the 11 studies recruiting patients and 8 not yet recruiting in the United States and worldwide, with eligibility criteria in plain English. Of these, 10 test a treatment and 9 are observational studies or registries; each card says which. Every trial comes from ClinicalTrials.gov.

Jump to the trial list, the site map, the pipeline timeline or the medication checker.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

19 active trials worldwide
Filter:
Sort:
RecruitingObservational study, no treatment givenRecently updatedNCT07914764

68Ga-labeled Cholecystokinin Receptor (CCK2R) Targeted Molecular Probes in Early Tumor Diagnosis

Intervention: Intravenous injection of 68Ga-YQ-CC05 for PET-CT examination

Sponsor: Nanjing First Hospital, Nanjing Medical University

Evaluate the safety of the novel radioactive nuclide-labeled cholecystokinin receptor (CCK2R) targeted molecular probe, 68Ga-YQ-CC05, in clinical application, and verify its effectiveness in tumor diagnosis.

Ages 18 Years to 75 Years1 location
Started Aug 2026Updated 2 weeks agoEst. Oct 2026
Not yet recruitingTreatment trialPhase 1Recently updatedNCT07252661

Study of ACC-1898 in Adult Participants With Advanced Solid Tumors

Intervention: ACC-1898

Sponsor: AccSalus Biosciences, Inc.

This is a research study of an experimental drug called ACC-1898. ACC-1898 is an oral tyrosine kinase inhibitor (TKI) that blocks several proteins kinases which may help cancer cells grow and spread.

Ages 18 Years+
Expected to start Jan 2027Updated 3 weeks agoEst. Jun 2028 (~1y 7m)
Not yet recruitingTreatment trialPhase 1Recently updatedNCT07661420

211At-MABG in Adults With Advanced Neuroendocrine Cancers

Intervention: 1 MBq/k of 211At-MABG Fractionated, 2 MBq/k1 of 211At-MABG Fractionated, 4 MBq/k of 211At-MABG Fractionated

Sponsor: University of Pennsylvania

Phase I dose escalation study of 211At-MABG in adults with advanced pheochromocytoma / paraganglioma (PPGL) or other NET-overexpressing cancers (as evidenced by positive MIBG imaging) who are refractory to, lacking, or ineligible for approved treatments. Phase 1 dose-escalation w...

Ages 18 Years+1 location
Expected to start Dec 2026Updated 1 month agoEst. Aug 2029 (~2y 8m)
RecruitingTreatment trialPhase 1/2Recently updatedNCT06814496

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Intervention: Tarlatamab, Concurrent Radiation Therapy, Sequential Radiation therapy

Sponsor: University of Arizona · Amgen

Phase I study to examine safety of the addition of concurrent tarlatamab with standard palliative and consolidative RT regimens , with a main cohort of N=20-24 patients with extracranial anatomic radiation sites.

Ages 18 Years to 99 Years3 locations
Started Sep 2025Updated 1 month agoEst. May 2030 (~3y 6m)
Not yet recruitingObservational study, no treatment givenRecently updatedNCT07621146

A Comparison of [68Ga]DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine Malignancies

Intervention: 68Ga-DOTATATE PET/CT, 18F-AmBF3-TATE PET/CT

Sponsor: British Columbia Cancer Agency

Neuroendocrine tumours (NETs) are generally slow growing, but some can be aggressive and resistant to treatment. Compared to healthy cells, the surface of these tumor cells has a greater number of molecules called somatostatin receptors (SSTR) which requires specific PET scan tra...

Ages 18 Years+1 location
Expected to start Nov 2026Updated 1 month agoEst. Jun 2027 (~7 months)
Find Medullary Thyroid Cancer trials near you, ranked by distance →
Active trial locations9 cities in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.
+1 more

Trial Pipeline

Jan 2021 to Nov 2031
2021
2023
2025
2027
2029
2031
now
Phase 1
Phase 2
Phase 3
Phase 4
Observational
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about Medullary Thyroid Cancer trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run a Medullary Thyroid Cancer foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Medullary Thyroid Cancer patient communities

Facebook groups, Reddit communities and YouTube channels where Medullary Thyroid Cancer patients, caregivers and advocacy groups talk.

Companies developing Medullary Thyroid Cancer treatments

Drugmakers that list Medullary Thyroid Cancer in their rare disease portfolio, 8 in all.

Questions people ask about Medullary Thyroid Cancer